Skip to main content
    E

    Edesa Biotech Inc (EDSA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.89
    -0.05 (-2.58%)

    Market Cap: $26.21M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Edesa Biotech Inc (EDSA) Financials: Revenue, Profit and Cash Flow

    Updated Aug 13, 2026. Financial statements from company filings, amounts in US dollars.

    Edesa Biotech reported revenue of $0 for the fiscal year ended Sep 30, 2025. That year, net income was -$7.19M, operating cash flow was -$7.32M and free cash flow was -$7.32M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$5.41M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Sep 2025, with an operating loss of $7.91M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$0N/AN/AN/AN/A
    Sep 2024$0N/AN/AN/AN/A
    Sep 2023$0N/AN/AN/AN/A
    Sep 2022$0-100.0%N/AN/AN/A
    Sep 2021$500-99.8%-23757.6%-4736266.4%-2668630.0%
    Sep 2020$328.80K-20.0%94.6%-1946.7%-1935.6%
    Sep 2019$410.87K+93.9%75.3%-689.3%-662.3%
    Sep 2018$211.85K-7.2%-110.2%-2397.1%-2378.6%
    Sep 2017$228.29K-82.0%-134.1%-2288.6%-2203.7%
    Sep 2016$1.27MN/A11.3%-386.0%-395.2%
    Annual, fiscal years ended Sep 2016 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Revenue$0$0$0$0$500$328.80K$410.87K$211.85K$228.29K$1.27M
    Cost of revenue$119.27K$186.05K$183.47K$118.19K$118.79K$17.60K$101.29K$445.32K$534.45K$1.13M
    Gross profit-$119.27K-$186.05K-$183.47K-$118.19K-$118.79K$311.20K$309.58K-$233.47K-$306.17K$143.86K
    Research and development$3.67M$2.88M$4.79M$13.34M$17.95M$3.33M$1.10M$2.09M$1.97M$1.73M
    Operating income-$7.91M-$7.01M-$9.22M-$18.37M-$23.68M-$6.40M-$2.83M-$5.08M-$5.22M-$4.91M
    Net income-$7.19M-$6.17M-$8.37M-$17.55M-$13.34M-$6.36M-$2.72M-$5.04M-$5.03M-$5.03M
    EBITDA-$7.07M-$6.13M-$9.22M-$17.47M-$13.22M-$6.34M-$2.83M-$4.85M-$4.85M-$4.87M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$50.92K$0$0$0$0$0$0$0$0$0-$1.12M
    Gross profit-$25.64K-$25.87K-$25.46K-$25.87K-$25.79K-$24.51K-$43.11K-$44.21K-$51.41K-$45.40K-$45.03K-$45.97K
    Operating income-$5.52M-$4.30M-$2.34M-$2.47M-$1.90M-$1.64M-$1.90M-$1.00M-$1.93M-$2.22M-$1.86M-$2.37M
    Net income-$5.41M-$4.22M-$2.25M-$2.23M-$1.75M-$1.59M-$1.62M-$962.05K-$1.67M-$1.86M-$1.68M-$1.72M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, cash and equivalents of $10.79M were 79.7% of total assets of $13.53M, against total liabilities of $1.08M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Total assets$13.53M$3.81M$8.89M$11.58M$14.58M$10.76M$5.72M$11.78M$7.72M$12.94M
    Current assets$11.51M$1.68M$6.44M$9.09M$12.09M$8.10M$5.64M$10.66M$6.76M$12.10M
    Cash and equivalents$10.79M$1.04M$5.36M$7.09M$7.84M$7.21M$5.03M$4.23M$4.57M$7.42M
    Total liabilities$1.08M$1.83M$1.84M$2.18M$1.53M$1.65M$461.63K$493.38K$320.95K$623.64K
    Short-term debtN/A$19.87K$74.71K$18.98K$78.81K$69.73KN/AN/AN/AN/A
    Shareholder equity$12.45M$1.98M$7.05M$9.39M$13.06M$9.11M$5.26M$11.29M$7.40M$12.31M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$12.72M$12.38M$14.71M$13.53M$14.80M$16.45M$4.16M$3.81M$5.23M$6.48M$7.83M$9.12M
    Total liabilities$3.91M$2.19M$756.16K$1.08M$672.67K$914.70K$1.90M$1.83M$2.36M$2.15M$1.99M$2.07M
    Cash and equivalents$10.33M$10.00M$12.05M$10.79M$12.36M$13.90M$1.56M$1.04M$2.04M$2.80M$4.27M$5.36M
    Shareholder equity$8.81M$10.20M$13.95M$12.45M$14.13M$15.54M$2.26M$1.98M$2.87M$4.32M$5.84M$7.05M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2025.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Operating cash flow-$7.32M-$4.89M-$6.64M-$12.28M-$13.66M-$4.99M-$4.85M-$4.62M-$4.70M-$4.51M
    Capital expenditures$0$0$3$5.66K$6.15K$34.34K$8.10K$382.81K$302.73K$402.27K
    Free cash flow-$7.32M-$4.89M-$6.64M-$12.28M-$13.67M-$5.02M-$4.85M-$5.00M-$5.00M-$4.91M
    Investing cash flowN/AN/AN/A-$5.66K-$6.15K$19.07K$6.42M-$4.47M$1.69M$557.41K
    Financing cash flow$17.03M$592.03K$4.83M$11.63M$14.17M$7.09M$7.09M$8.77MN/A$7.31M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$3.05M-$2.05M-$2.09M-$1.77M-$1.75M-$2.38M-$1.52M-$967.04K-$856.48K-$1.68M-$1.41M-$1.48M
    Capital expenditures$7$3$4$3$0$3$3$0N/A$4$0$5
    Free cash flow-$3.05M-$2.05M-$2.09M-$1.77M-$1.75M-$2.38M-$1.52M-$967.04KN/A-$1.68M-$1.41M-$1.48M
    Last 12 quarters

    Frequently Asked Questions About EDSA

    What is Edesa Biotech's annual revenue?

    Edesa Biotech reported revenue of $0 for the fiscal year ended Sep 30, 2025.

    Is Edesa Biotech profitable?

    No. Edesa Biotech reported net income of -$7.19M for the fiscal year ended Sep 30, 2025.

    How much free cash flow does EDSA generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of -$7.32M minus capital expenditures of $0 produced free cash flow of -$7.32M.

    How much debt does Edesa Biotech have?

    The balance sheet dated Sep 30, 2025 reported cash and equivalents of $10.79M.